Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise
This online study, using a web-crawler and then manual analysis of the data, found 994 previously unknown psychedelic molecules.
Authors
- Catalani, V.
- Corkery, J. M.
- Guirguis, A.
Published
Abstract
Psychedelics alter the perception of reality through agonist or partial agonist interaction with the 2A serotoninergic receptor. They are classified as phenethylamines, tryptamines and lysergamides. These classes, according to the United Nations Office on Drugs and Crime (UNODC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), account for an important percentage of the new psychoactive substances (NPS) current scenario. The paper aimed at: a) identifying and categorising psychedelic molecules from a list of psychonautwebsites and NPS online resources; and b) comparing the NPSfinderⓇ results with those from the European and United Nations databases. A crawling software (i.e. ‘NPSfinderⓇ’) was created to automatically scan, 24/7, a list of URLs and to extract a range of information (chemical/street names, chemical formulae, etc.) to facilitate NPS identification. Data collected were manually analysed and compared with the EMCDDA and UNODC databases. The overall number of psychedelic NPS detected by NPSfinderⓇ (November 2017-February 2020) was 1344, almost ten-times higher than that reported by the UNODC and EMCDDA combined. Of these, 994 previously unknown molecules were identified as (potential) novel psychedelics, suggesting a strong discrepancy between online and real-world NPS scenarios. The results show the interest of psychonauts, and maybe of the much larger community of ‘recreational’ drug users, towards psychedelics. Moreover, examining online scenario may help in assessing the availability in the real world of psychedelic NPS; understanding drug trends; and in possibly predicting future drug scenarios
Research Summary of 'Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise'
Introduction
Catalani and colleagues frame psychedelics as a class of substances—principally tryptamines, lysergamides and a subset of phenethylamines—that act as agonists or partial agonists at the 5-HT2A serotonin receptor and produce characteristic alterations of perception and consciousness. The authors note that the early 2000s saw a proliferation of synthetic analogues within these chemical families, many of which have been described as Novel Psychoactive Substances (NPS). These synthetic derivatives frequently lack formal pharmacological characterisation, and several have been implicated in acute intoxications and fatalities. Parallel to chemical diversification, an online community of ‘‘e-psychonauts’’ has emerged who experiment with and disseminate information about psychedelic NPS via forums and other web platforms, potentially shaping demand and the online visibility of new compounds. The study set out to exploit this online activity by using an automated web crawler (NPS finder®) to identify and categorise psychedelic molecules discussed on psychonaut websites and other surface‑web NPS resources, and to compare the crawler’s output with entries in the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and UNODC databases. The investigators restricted their operational definition of psychedelics to tryptamines, lysergamides and phenethylamines with psychedelic activity, and aimed to assess whether web‑based surveillance could reveal substances not yet recorded in official databases. The work is presented as part of a broader programme comparing online signals with real‑world detection of NPS.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Topic
- APA Citation
Catalani, V., Corkery, J. M., Guirguis, A., Napoletano, F., Arillotta, D., Zangani, C., Vento, A., & Schifano, F. (2021). Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise. European Neuropsychopharmacology, 49, 69-92. https://doi.org/10.1016/j.euroneuro.2021.03.006
References (12)
Papers cited by this study that are also in Blossom
Green, A. R. · British Journal of Pharmacology (2009)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)
Nichols, D. E. · Current Topics in Behavioral Neurosciences (2017)
Nichols, D. E. · Pharmacological Reviews (2016)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Souza, D. C. D., Pérez, C., Papaseit, E. et al. · Frontiers in Pharmacology (2018)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Show all 12 referencesShow fewer
Tittarelli, R., Mannocchi, G., Pantano, F. et al. · Current Neuropharmacology (2015)
Winter, J. C. · Psychopharmacology (2008)
Cited By (2)
Papers in Blossom that reference this study
Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G. et al. · Molecular Psychiatry (2024)
Matzopoulos, R., Morlock, A., Morlock, R. et al. · MedRvix (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.